Eversept Partners LP Purchases 19,620 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Share on StockTwits

Eversept Partners LP boosted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 51.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 57,849 shares of the pharmaceutical company’s stock after purchasing an additional 19,620 shares during the period. Vertex Pharmaceuticals comprises 3.0% of Eversept Partners LP’s holdings, making the stock its 11th largest position. Eversept Partners LP’s holdings in Vertex Pharmaceuticals were worth $10,608,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in VRTX. Daiwa Securities Group Inc. lifted its position in Vertex Pharmaceuticals by 0.5% during the second quarter. Daiwa Securities Group Inc. now owns 11,806 shares of the pharmaceutical company’s stock worth $2,165,000 after acquiring an additional 61 shares during the last quarter. Signaturefd LLC raised its position in shares of Vertex Pharmaceuticals by 7.6% in the second quarter. Signaturefd LLC now owns 1,016 shares of the pharmaceutical company’s stock valued at $186,000 after buying an additional 72 shares in the last quarter. ETF Managers Group LLC raised its position in shares of Vertex Pharmaceuticals by 9.1% in the first quarter. ETF Managers Group LLC now owns 877 shares of the pharmaceutical company’s stock valued at $161,000 after buying an additional 73 shares in the last quarter. Pittenger & Anderson Inc. raised its position in shares of Vertex Pharmaceuticals by 64.7% in the first quarter. Pittenger & Anderson Inc. now owns 191 shares of the pharmaceutical company’s stock valued at $35,000 after buying an additional 75 shares in the last quarter. Finally, Next Capital Management LLC raised its position in shares of Vertex Pharmaceuticals by 84.4% in the second quarter. Next Capital Management LLC now owns 166 shares of the pharmaceutical company’s stock valued at $30,000 after buying an additional 76 shares in the last quarter. Hedge funds and other institutional investors own 95.03% of the company’s stock.

NASDAQ:VRTX traded up $1.31 during mid-day trading on Friday, reaching $173.76. The stock had a trading volume of 37,137 shares, compared to its average volume of 1,013,137. The stock has a 50-day simple moving average of $178.26 and a two-hundred day simple moving average of $177.80. The stock has a market capitalization of $43.96 billion, a PE ratio of 61.40, a P/E/G ratio of 2.23 and a beta of 1.37. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.74 and a quick ratio of 3.63. Vertex Pharmaceuticals Incorporated has a 12 month low of $151.80 and a 12 month high of $195.81.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Wednesday, July 31st. The pharmaceutical company reported $0.99 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.24. The firm had revenue of $941.29 million for the quarter, compared to analysts’ expectations of $884.66 million. Vertex Pharmaceuticals had a net margin of 64.13% and a return on equity of 21.73%. The company’s revenue was up 25.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.94 earnings per share. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post 3.41 EPS for the current year.

Vertex Pharmaceuticals announced that its Board of Directors has authorized a stock repurchase program on Wednesday, July 31st that allows the company to repurchase $500.00 million in outstanding shares. This repurchase authorization allows the pharmaceutical company to reacquire up to 1.2% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

In other Vertex Pharmaceuticals news, EVP David Altshuler sold 12,501 shares of the business’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $186.38, for a total transaction of $2,329,936.38. Following the sale, the executive vice president now owns 35,803 shares of the company’s stock, valued at $6,672,963.14. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Jeffrey M. Leiden sold 56,030 shares of the business’s stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $175.39, for a total transaction of $9,827,101.70. Following the sale, the chief executive officer now directly owns 162,317 shares in the company, valued at approximately $28,468,778.63. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 93,641 shares of company stock worth $16,705,255. Insiders own 0.70% of the company’s stock.

A number of equities research analysts have recently weighed in on VRTX shares. Maxim Group reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Friday, August 2nd. ValuEngine downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. BidaskClub downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 28th. HC Wainwright reiterated a “buy” rating and issued a $220.00 price target on shares of Vertex Pharmaceuticals in a research report on Thursday, August 1st. Finally, Goldman Sachs Group upgraded shares of Vertex Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price target for the company from $226.00 to $254.00 in a research report on Tuesday, September 3rd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. Vertex Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $210.68.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

Featured Story: What does the Dow Jones Industrial Average (DJIA) measure?

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.